Thomas Bradberry
Internal Medicine · Newberry, SCNPI 1649283748
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.3% of the total across 376 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 34 manufacturers, the largest accounting for just 17.6% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2020 at $1,767 and has fallen 99.1% since, to $15 in 2025. Among internal medicine clinicians in SC with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 376 payments — averaging $18.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$1K
- Novo Nordisk$834
- AstraZeneca$792
- Lilly USA, LLC$577
- Pfizer$351
- Esperion Therapeutics, Inc.$316
- plus $3K from 28 others
What the payments were for
- Food & beverage$6,93998%
- Education$391%
- Other$831%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 58 | $1,242 |
| Novo Nordisk | 47 | $834 |
| AstraZeneca | 44 | $792 |
| Lilly USA, LLC | 37 | $577 |
| Pfizer | 26 | $351 |
| Esperion Therapeutics, Inc. | 5 | $316 |
| Novartis | 15 | $308 |
| Merck | 18 | $276 |
| Bayer | 6 | $264 |
| Abbott | 13 | $237 |
| Amarin Pharma, Inc. | 12 | $213 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 12 | $199 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $164 |
| Dexcom, Inc. | 9 | $150 |
| AbbVie | 11 | $149 |
| Johnson & Johnson | 9 | $136 |
| Boehringer Ingelheim | 7 | $125 |
| Sanofi-aventis U.S. LLC | 6 | $100 |
| Daiichi Sankyo Inc. | 4 | $87 |
| Baxter Healthcare | 1 | $83 |
| Xeris Pharmaceuticals, Inc. | 4 | $79 |
| E.r. Squibb & Sons, L.L.C. | 5 | $70 |
| Nestle Healthcare Nutrition Inc. | 3 | $48 |
| Alnylam Pharmaceuticals Inc. | 2 | $41 |
| Ironwood Pharmaceuticals, Inc | 2 | $37 |
| Eisai Inc. | 2 | $28 |
| Ultragenyx Pharmaceutical Inc. | 1 | $27 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $24 |
| Inspire Medical Systems, Inc. | 1 | $22 |
| Otsuka America Pharmaceutical, Inc. | 1 | $19 |
| Mylan Specialty L.p. | 1 | $18 |
| Exact Sciences | 1 | $17 |
| Bioxcel Therapeutics, Inc. | 1 | $17 |
| GSK | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,061 in reported general payments places this provider in the 90th percentile of 1,498 internal medicine providers in South Carolina.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 52 | $53,422 |
| EliquisApixaban | 29 | $20,242 |
| JardianceEmpagliflozin | 24 | $17,508 |
| FarxigaDapagliflozin Propanediol | 19 | $12,499 |
| Breo ElliptaFluticasone/Vilanterol | 12 | $4,799 |
| Rosuvastatin Calcium | 142 | $2,808 |
| Humalog Kwikpen U-100Insulin Lispro | 11 | $1,719 |
| Famotidine | 75 | $1,345 |
| Memantine Hcl | 19 | $1,205 |
| Atorvastatin Calcium | 129 | $1,011 |
| Amlodipine Besylate | 209 | $945 |
| Omeprazole | 73 | $894 |
| Escitalopram Oxalate | 108 | $889 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 35 | $836 |
| Bupropion Hcl SrBupropion Hcl | 18 | $769 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $834 | $53,42252 claims |
| PfizerEliquis | $351 | $20,24229 claims |
| Boehringer IngelheimJardiance | $125 | $17,50824 claims |
| AstraZenecaFarxiga | $792 | $12,49919 claims |
| GSKBreo Ellipta | $13 | $4,79912 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,498 internal medicine providers in South Carolina.
Other internal medicine in Newberry
- Mark DavisNewberry$11K
- Jerry BackNorth Charleston$322K
- Jan BasileCharleston$278K
- Mark PurcellGreenville$165K
- John CleekCharleston$136K
- William BunnHilton Head Island$125K
- Zion LammGreenville$118K
- Bruce GrayGreenville$111K
- Leonard AlsfeldCharleston$91K
- Edward Botse-BaidooMyrtle Beach$90K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.